Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions
Jianhua Ding1, Chaihong Yeong1
1Taylor's University, Subang Jaya, Selangor, Malaysia.
Abstract:
Small cell lung cancer (SCLC) remains one of the most aggressive and challenging malignancies to treat, with limited therapeutic options and poor outcomes. Recent advances in understanding SCLC biology have identified Delta-like ligand 3 (DLL3) as a promising target for novel therapies. This review explores the evolving landscape of DLL3-targeted therapies in SCLC, examining their mechanistic basis, preclinical promise, and clinical development. We discuss various therapeutic modalities, including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), chimeric antigen receptor T-cell (CAR-T) therapies, and emerging approaches such as near-infrared photoimmunotherapy (NIR-PIT) and radiopharmaceutical therapy (RPT). The review highlights the challenges encountered in translating these promising approaches into clinical practice, including the setbacks faced by early DLL3-targeted therapies like Rovalpituzumab Tesirine (Rova-T). We also explore potential strategies to overcome these obstacles, emphasizing the need for a more nuanced understanding of DLL3 biology and its role in SCLC pathogenesis. The integration of cutting-edge technologies and interdisciplinary collaboration is proposed as a path forward to optimize DLL3-targeted therapies and improve outcomes for SCLC patients. This comprehensive overview provides insights into the current state and future directions of DLL3-targeted therapies, underscoring their potential to revolutionize SCLC treatment paradigms.
Insights
Delta-like ligand 3 (DLL3) is a promising target for small cell lung cancer (SCLC). This review examines DLL3-targeted therapies, including antibody-drug conjugates and CAR-T cells, and discusses challenges and future strategies for SCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options.
- Delta-like ligand 3 (DLL3) has emerged as a key therapeutic target in SCLC.
- Understanding DLL3 biology is crucial for developing effective SCLC therapies.
Purpose of the Study:
- To review the current landscape of DLL3-targeted therapies for SCLC.
- To examine the mechanisms, preclinical data, and clinical development of these therapies.
- To identify challenges and propose strategies for optimizing DLL3-targeted treatments.
Main Methods:
- Literature review of preclinical and clinical studies on DLL3-targeted therapies in SCLC.
- Analysis of various therapeutic modalities: antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), chimeric antigen receptor T-cell (CAR-T) therapies, near-infrared photoimmunotherapy (NIR-PIT), and radiopharmaceutical therapy (RPT).
- Discussion of challenges and potential solutions, including Rovalpituzumab Tesirine (Rova-T) setbacks.
Main Results:
- DLL3-targeted therapies show significant preclinical promise in SCLC.
- Clinical development has faced challenges, with some early therapies like Rova-T experiencing setbacks.
- Diverse therapeutic approaches are being investigated, highlighting the complexity of DLL3 targeting.
Conclusions:
- DLL3-targeted therapies hold potential to revolutionize SCLC treatment.
- Overcoming clinical challenges requires a deeper understanding of DLL3 biology and SCLC pathogenesis.
- Interdisciplinary collaboration and advanced technologies are key to optimizing these novel therapies.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
